Skip to main content

Table 1 JCPyV-DNA q-PCR in plasma, urine and PBMCs samples of 21 MS patients in 1-year follow-up

From: Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

 

Plasma*,**

Urine*,**

PBMCs*,**

 

Pts.

STRATIFY JCV® t0†

t0

t1

t2

t3

t0

t1

t2

t3

t0

t1

t2

t3

STRATIFY JCV® t3†

MS 1

Pos

2.70

 

3.26

        

3.03

Pos

MS 2‡

Pos

2.85

2.67

/

/

  

/

/

 

2.56

/

/

Pos

MS 3

Neg

    

3.7

3.48

6.01

3.86

    

Pos

MS 4‡

Neg

   

3.15

   

3.32

    

Pos

MS 5‡

Neg

    

4.1

4.58

7.30

6.18

    

Pos

MS 6

Neg

   

2.68

        

Pos

MS 7

Neg

       

5.47

    

Pos

MS 8

Neg

       

4.74

    

Pos

MS 9

Neg

            

Neg

MS 10

Neg

            

Neg

MS 11

Neg

      

3.77

     

Neg

MS 12

Neg

         

3.72

  

Neg

MS 13

Neg

            

Neg

MS 14

Neg

            

Neg

MS 15

Neg

            

Neg

MS 16

Neg

            

Neg

MS 17

Neg

            

Neg

MS 18‡

Neg

   

3.00

        

Neg

MS 19‡

Neg

 

/

/

  

/

/

  

/

/

 

Neg

MS 20‡

Neg

/

/

  

/

/

6.04

 

/

/

  

Neg

MS 21

Neg

            

Neg

Median JCPyV load**

2.77

2.67

3.26

3.00

3.90

4.03

6.03

4.74

 

3.14

 

3.03

 

p value§

       

0.04

     
  1. pos: positive; neg: negative.
  2. * 78 urine, 78 plasma and 78 PBMCs samples were collected at baseline (t0) and after 4 (t1), 8 (t2), and 12 (t3) months of therapy.
  3. † 2-step virus-like particle-based enzyme-linked immunosorbed assay (ELISA) (STRATIFY JCV®) was performed at t0 and t3, to detect specific anti-JC virus antibodies in serum of the 21 enrolled subjects.
  4. ** JCPyV loads values are expressed as log10 genome equivalent (gEq)/mL in urine and in plasma, and as log10 gEq/106 cells in PBMCs and they are indicated in boldface.
  5. § By χ2 test: positive STRATIFY JCV® patients after 1-year of natalizumab treatment vs negative STRATIFY JCV® patients after 1 year of natalizumab treatment. p value < 0.05 only for JCPyV DNA positive urine samples.
  6. ‡ patient MS2 suspended natalizumab for allergic reaction; patients MS19 and MS20 showed poor compliance; patient MS18 suspended the biological therapy for uterine cancer and papillomatosis after 11 months of natalizumab infusions; patient MS4 did not perform 2 natalizumab infusions because of Escherichia coli urinary infection; patient MS5 showed clinical relapse during follow up.
Back to article page

Virology Journal

ISSN: 1743-422X